Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
Souleymane Mahamadou BassirouTom DecrooSaïdou MamadouAlphazazi SoumanaIbrahim Mamane LawanAssiatou Gagara-IssoufouEric AdehossiNimer Ortuño-GutiérrezLutgarde LynenLeen RigoutsBouke Catherine de JongArmand Van DeunAlberto PiubelloPublished in: International health (2022)
If fluoroquinolone resistance is excluded or rare, it is beneficial to use fluoroquinolone as the core drug for a first RR-TB treatment regimen and to safeguard bedaquiline for those in need of retreatment.